Mr. Rabin Will Discuss Two Ongoing Clinical Trials in the U.S. and Plans for the First Human Embryonic Stem Cell Trial In Europe Using Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelial (RPE) Cells to Treat Macular Degeneration
MARLBOROUGH, Mass. — Oct. 3, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s chairman and CEO, Gary Rabin, will be presenting at the 2011 World Stem Cell Summit on Wednesday, Oct. 5, at the Pasadena Convention Center in Pasadena, Calif.
Mr. Rabin’s presentation will provide an update on the company’s two ongoing human clinical trials in the U.S. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt’s Macular Dystrophy using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. He will also discuss plans for the first human embryonic stem cell clinical trial in Europe. The company recently received regulatory clearance to initiate the trial.
After the conference, an archived copy of Mr. Rabin’s PowerPoint presentation will be available on the “conference presentations section” of ACT’s website.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
CEOcast, Inc., James Young, 212-732-4300
ACT Corporate Communications, Bill Douglass, 646-450-3615
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292